Literature DB >> 20947489

A mouse model for human anal cancer.

Marie K Stelzer1, Henry C Pitot, Amy Liem, Johannes Schweizer, Charles Mahoney, Paul F Lambert.   

Abstract

Human anal cancers are associated with high-risk human papillomaviruses (HPV) that cause other anogenital cancers and head and neck cancers. As with other cancers, HPV16 is the most common high-risk HPV in anal cancers. We describe the generation and characterization of a mouse model for human anal cancer. This model makes use of K14E6 and K14E7 transgenic mice in which the HPV16 E6 and E7 genes are directed in their expression to stratified squamous epithelia. HPV16 E6 and E7 possess oncogenic properties including, but not limited to, their capacity to inactivate the cellular tumor suppressors p53 and pRb, respectively. Both E6 and E7 were found to be functionally expressed in the anal epithelia of K14E6/K14E7 transgenic mice. To assess the susceptibility of these mice to anal cancer, mice were treated topically with dimethylbenz[a]anthracene (DMBA), a chemical carcinogen that is known to induce squamous cell carcinomas in other sites. Nearly 50% of DMBA-treated HPV16 E6/E7 transgenic mice showed overt signs of tumors, whereas none of the like-treated nontransgenic mice showed tumors. Histopathologic analyses confirmed that the HPV16 transgenic mice were increased in their susceptibility to anal cancers and precancerous lesions. Biomarker analyses demonstrated that these mouse anal cancers exhibit properties that are similar to those observed in HPV-positive precursors to human anal cancer. This is the first mouse model for investigating the contributions of viral and cellular factors in anal carcinogenesis, and should provide a platform for assessing new therapeutic modalities for treating and/or preventing this type of cancer. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947489      PMCID: PMC3006089          DOI: 10.1158/1940-6207.CAPR-10-0086

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  27 in total

1.  Ki-ras oncogene mutations in non-HPV-associated anal carcinoma.

Authors:  L R Hiorns; J H Scholefield; J G Palmer; N A Shepherd; I B Kerr
Journal:  J Pathol       Date:  1990-06       Impact factor: 7.996

2.  Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene.

Authors:  R Herber; A Liem; H Pitot; P F Lambert
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the complete carcinogenesis process and by the initiation-promotion regimen.

Authors:  A K Verma; E A Conrad; R K Boutwell
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

4.  The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals.

Authors:  S Song; H C Pitot; P F Lambert
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 5.  Molecular biology of squamous cell carcinoma of the anus.

Authors:  P Gervaz; B Hirschel; P Morel
Journal:  Br J Surg       Date:  2006-05       Impact factor: 6.939

Review 6.  The etiology and epidemiology of anal cancer.

Authors:  Mark Lane Welton; Francis E Sharkey; Morton S Kahlenberg
Journal:  Surg Oncol Clin N Am       Date:  2004-04       Impact factor: 3.495

7.  Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis.

Authors:  Rebeccah R Riley; Stefan Duensing; Tiffany Brake; Karl Münger; Paul F Lambert; Jeffrey M Arbeit
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

8.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.

Authors:  T Kiyono; S A Foster; J I Koop; J K McDougall; D A Galloway; A J Klingelhutz
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962

9.  Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity.

Authors:  S N Khleif; J DeGregori; C L Yee; G A Otterson; F J Kaye; J R Nevins; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo.

Authors:  Scott J Balsitis; Julien Sage; Stefan Duensing; Karl Münger; Tyler Jacks; Paul F Lambert
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

View more
  28 in total

Review 1.  Anal cancer and intraepithelial neoplasia: epidemiology, screening and prevention of a sexually transmitted disease.

Authors:  Richard J Medford; Irving E Salit
Journal:  CMAJ       Date:  2014-12-15       Impact factor: 8.262

2.  Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer.

Authors:  Brooks L Rademacher; Kristina A Matkowskyj; Emily D LaCount; Evie H Carchman
Journal:  Eur J Cancer Prev       Date:  2019-11       Impact factor: 2.497

Review 3.  Model systems to study the life cycle of human papillomaviruses and HPV-associated cancers.

Authors:  Louise T Chow
Journal:  Virol Sin       Date:  2015-04-23       Impact factor: 4.327

4.  Validation of an HPV16-mediated carcinogenesis mouse model.

Authors:  Katherine De Azambuja; Provabati Barman; Joy Toyama; David Elashoff; Gregory W Lawson; Lisa K Williams; Kristofer Chua; Deborah Lee; Joseph J Kehoe; Andre Brodkorb; Rebecca Schwiebert; Scott Kitchen; Aamir Bhimani; Dorothy J Wiley
Journal:  In Vivo       Date:  2014 Sep-Oct       Impact factor: 2.155

5.  Rapamycin inhibits anal carcinogenesis in two preclinical animal models.

Authors:  Marie K Stelzer; Henry C Pitot; Amy Liem; Denis Lee; Gregory D Kennedy; Paul F Lambert
Journal:  Cancer Prev Res (Phila)       Date:  2010-12

6.  Dominant role of HPV16 E7 in anal carcinogenesis.

Authors:  Marie K Thomas; Henry C Pitot; Amy Liem; Paul F Lambert
Journal:  Virology       Date:  2011-10-13       Impact factor: 3.616

7.  The role of pharmacologic modulation of autophagy on anal cancer development in an HPV mouse model of carcinogenesis.

Authors:  Brooks L Rademacher; Kristina A Matkowskyj; Louise M Meske; Alexis Romero; Hana Sleiman; Evie H Carchman
Journal:  Virology       Date:  2017-04-18       Impact factor: 3.616

Review 8.  Human papillomavirus infections: warts or cancer?

Authors:  Louise T Chow; Thomas R Broker
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

9.  Differential gene expression between skin and cervix induced by the E7 oncoprotein in a transgenic mouse model.

Authors:  E Ibarra Sierra; J Díaz Chávez; E M Cortés-Malagón; L Uribe-Figueroa; A Hidalgo-Miranda; P F Lambert; P Gariglio
Journal:  Virology       Date:  2012-09-11       Impact factor: 3.616

10.  Human papillomavirus oncogenes reprogram the cervical cancer microenvironment independently of and synergistically with estrogen.

Authors:  Megan E Spurgeon; Johan A den Boon; Mark Horswill; Sonalee Barthakur; Omid Forouzan; Janet S Rader; David J Beebe; Avtar Roopra; Paul Ahlquist; Paul F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.